The chemotherapy-free oral regimen showed both central nervous system (CNS) penetration and activity across ABL1 mutants, supporting its potential for this high-risk pediatric patient population, wrote the study’s authors, led by Jinlia Zhang, DM, of the Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China.

Data from the trial, led by Elias Jabbour, MD, of The University of Texas MD Anderson Cancer Center, were presented at the 2026 American Society of Clinical Oncology Annual Meeting in Chicago, Illinois.